Vertex’s second try at a rare lung disorder

VX-814, Vertex’s first foray into the rare respiratory disease alpha-1 antitrypsin deficiency, ended with clinical failure and the loss of $14bn of market cap. Now a vital mid-stage clinical study of VX-864, a separate asset for the same condition, is set to read out by mid-year.